BiondVax Provides Third Quarter 2017 Financial Results and Update
November 28, 2017 at 11:16 AM EST
BiondVax Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced its financial results for the quarter ended September 30, 2017.
